PDL BioPharma, Inc.
PDL BIOPHARMA, INC. (Form: 8-K, Received: 11/14/2017 06:02:51)


 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): November 14, 2017

PDL BioPharma, Inc.

(Exact name of Company as specified in its charter)

000-19756
(Commission File Number)


Delaware
 
94-3023969
(State or Other Jurisdiction of Incorporation)
 
(I.R.S. Employer Identification No.)


932 Southwood Boulevard
Incline Village, Nevada 89451
(Address of principal executive offices, with zip code)

(775) 832-8500
(Company’s telephone number, including area code)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

¨      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
 






Item 7.01 Regulation FD Disclosure.
 
Beginning on November 14, 2017, PDL BioPharma, Inc. (the Company) will make presentations and participate in 
conferences with investors and analysts during the Jefferies 2017 London Healthcare Conference in London, UK. A copy of the Company's presentation materials has been posted to the Company's website and is attached hereto as Exhibit 99.1.

Limitation of Incorporation by Reference

In accordance with General Instruction B.2. of Form 8-K, this information, including the Exhibit, is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Current Report on Form 8-K will not be deemed an admission as to the materiality of any information that is required to be disclosed solely by Regulation FD.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.
 
Description
 
 
 
99.1
 

Cautionary Statements

This filing and the presentation include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Important factors that could impair the Company’s royalty assets or business are disclosed in the “Risk Factors” contained in the Company’s 2016 Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2017, and updated in subsequent filings. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.






SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PDL BIOPHARMA, INC.
(Company)
 
 
 
By:
 
/s/ John P. McLaughlin
 
 
John P. McLaughlin
 
 
Chief Executive Officer




Dated: November 14, 2017






Exhibit Index


Exhibit No.
 
Description
99.1
 





Exhibit 99.1

SLIDE1A53.JPG





SLIDE2A53.JPG





SLIDE3A53.JPG





SLIDE4A53.JPG





SLIDE5A53.JPG





SLIDE6A53.JPG





SLIDE7A53.JPG





SLIDE8A51.JPG





SLIDE9A50.JPG





SLIDN39.JPG





SLIDN40.JPG





SLIDN41.JPG





SLIDN42.JPG





SLIDN43.JPG





SLIDN44.JPG





SLIDN45.JPG





SLIDN46.JPG





SLIDN47.JPG





SLIDN48.JPG





SLIDN49.JPG





SLIDN50.JPG





SLIDN51.JPG





SLIDN52.JPG





SLIDN53.JPG





SLIDN54.JPG





SLIDN55.JPG





SLIDN56.JPG





SLIDN57.JPG





SLIDN58.JPG





SLIDN59.JPG





SLIDN60.JPG





SLIDN61.JPG





SLIDN62.JPG





SLIDN63.JPG





SLIDN64.JPG





SLIDN65.JPG





SLIDN66.JPG





SLIDN67.JPG





SLIDN68.JPG





SLIDN69.JPG





SLIDN70.JPG





SLIDN71.JPG





SLIDN72.JPG





SLIDN73.JPG





SLIDN74.JPG





SLIDN75.JPG





SLIDN76.JPG





SLIDN77.JPG





SLIDN78.JPG





SLIDN79.JPG





SLIDN80.JPG





SLIDN81.JPG





SLIDN82.JPG





SLIDN83.JPG





SLIDN84.JPG





SLIDN85.JPG





SLIDN86.JPG





SLIDN87.JPG